Update shared on17 Sep 2025
Fair value Decreased 2.43%Aspen Pharmacare Holdings' consensus price target has decreased to ZAR120.60, reflecting concerns over a sharply higher future P/E and a substantial decline in net profit margin.
What's in the News
- Aspen Pharmacare Holdings Limited announced an annual dividend of ZAR 2.1100 per share.
Valuation Changes
Summary of Valuation Changes for Aspen Pharmacare Holdings
- The Consensus Analyst Price Target has fallen slightly from ZAR123.60 to ZAR120.60.
- The Future P/E for Aspen Pharmacare Holdings has significantly risen from 6.99x to 12.59x.
- The Net Profit Margin for Aspen Pharmacare Holdings has significantly fallen from 24.03% to 13.23%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.